Mesityl-guanidin | 46167-49-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Mesityl-guanidin
• 英文别名: 1-Mesitylguanidine；2-(2,4,6-trimethylphenyl)guanidine
• CAS: 46167-49-1
• 化学式: C₁₀H₁₅N₃
• 分子量: 177.249
• InChiKey: GLKSRNURCQQYOR-UHFFFAOYSA-N

物化性质

• 沸点：
  270.7±50.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  氰胺 、 2,4,6-三甲基苯胺盐酸盐 以 乙醇 为溶剂， 生成 Mesityl-guanidin
  参考文献：
  名称：

  Die dirigierende Wirkung der Guanidinium-Gruppe

  摘要：

  N-氯基苯基脲的表达只有在特殊情况下才能成功，因为通常会发生氧化性替代反应。这些N-氯衍生物在硫酸中以核氯化的形式存在。以N-氯-N'-苯基-N'-甲基脲为例进行的同分异构体比例研究表明，其比例为o:m:p = 21:17:62。使用N-氯-N'-正丁基脲对N-苯基-N-甲基脲进行氯化时也得到了相同的结果。因此，在这两种情况下，尽管它们带有正电荷，脲基团仍然表现为一级取代基。

  DOI：

  10.1515/znb-1965-1206

文献信息

• [EN] CHIRAL GUANIDINES, SALTS THEREOF, METHODS OF MAKING CHIRAL GUANIDINES AND SALTS THEREOF, AND USES OF CHIRAL GUANIDINES AND SALTS THEREOF IN THE PREPARATION OF ENANTIOMERICALLY PURE AMINO ACIDS<br/>[FR] GUANIDINES CHIRALES, SELS DE CELLES-CI, PROCÉDÉS DE FABRICATION DE GUANIDINES CHIRALES ET DE LEURS SELS, ET UTILISATIONS DE GUANIDINES CHIRALES ET DE LEURS SELS DANS LA PRÉPARATION D'ACIDES AMINÉS ÉNANTIOMÉRIQUEMENT PURS
  申请人：FU RUI

  公开号：WO2021081677A1

  公开（公告）日：2021-05-06

  Provided are compounds and salts having a structure of Formula (I) or (II): (I), and (II) wherein: both of the chiral carbon atoms denoted by "*" are both in the R configuration or both in the S configuration. Compounds and salts of Formulae (I) and (II) are useful in the preparation of enantiomerically pure amino acids. Conversion of amino acids to D-form from any of L-form, racemate or other enantiomerically impure mixtures or conversion of amino acids to L-form from any of D-form, racemate or other enantiomerically impure mixtures is disclosed.

  提供具有Formula (I)或(II)结构的化合物和盐：(I)和(II)其中：由"*"表示的两个手性碳原子均为R构型或均为S构型。Formulae (I)和(II)的化合物和盐在制备对映异构体纯氨基酸方面具有用途。公开了将氨基酸从任何L形式，混合物或其他对映异构不纯混合物转化为D形式，或将氨基酸从任何D形式，混合物或其他对映异构不纯混合物转化为L形式的方法。
• Heterocyclic derivatives as CRF antagonists
  申请人：Roche Palo Alto LLC

  公开号：US20040224964A1

  公开（公告）日：2004-11-11

  This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I wherein X 1 is (CH 2 ) n or CO, n is 0 to 2 and R 1 , R 2 , R 3 and R 4 are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for their use as therapeutic agents. 1

  这项发明涉及一般为CRF-1受体拮抗剂的化合物，其表示为公式I，其中X1为(CH2)n或CO，n为0至2，R1、R2、R3和R4如规范中定义；或其各个异构体、拉氏或非拉氏混合物，或其药用可接受盐。该发明还涉及制备这类化合物的方法，含有这类化合物的药物组合物，以及它们作为治疗剂的使用方法。
• Pyrrolopyrimidine Derivatives
  申请人：Bischoff P. Francois

  公开号：US20070270588A1

  公开（公告）日：2007-11-22

  According to the present invention, there is provided an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastro-intestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc. A pyrrolopyrimidine derivative represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

  根据本发明，提供了一种CRF受体拮抗剂，作为治疗或预防CRF参与的疾病的药物，如抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃肠疾病、药物依赖、脑梗塞、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、斑秃、肠易激综合征、睡眠障碍、癫痫、皮炎、精神分裂症、疼痛等。以下式[I]所表示的吡咯吡嘧啶衍生物对CRF受体具有高亲和力，并对CRF参与的疾病有效。
• CURABLE COMPOSITION
  申请人：Kaneka Corporation

  公开号：EP1990371A1

  公开（公告）日：2008-11-12

  The present invention has its object to provide a curable composition which comprises a reactive silyl group-containing organic polymer, does not contain, as a silanol condensation catalyst, any organotin type curing catalyst currently of concern because of the toxic feature thereof, is excellent in surface curability and depth curability and, further, can provide cured products excellent in adhesiveness; the above obj ect can be achieved by a curable composition which comprises: an organic polymer (A) containing a silicon-containing group capable of crosslinking under siloxane bond formation; and a guanidine compound (B-1), as a silanol condensation catalyst (B), represented by the general formula (1):         R1N=C(NR12)2     (1) (wherein one of the five R1s is an aryl group and the other four R1s each independently is a hydrogen atom or a hydrocarbon group in which the carbon atom at position 1 is saturated).

  本发明的目的是提供一种可固化组合物，该组合物包括含活性硅烷基团的有机聚合物，作为硅烷醇缩合催化剂，不含任何目前因其毒性特征而受到关注的有机锡类固化催化剂，具有优异的表面固化性和深度固化性，而且，可提供具有优异粘合性的固化产品；上述目的可通过一种可固化组合物来实现，该组合物包括：含硅烷基团的有机聚合物(A)；作为硅烷醇缩合催化剂(B)的胍化合物(B-1)：一种有机聚合物 (A)，其中含有能在硅氧烷键形成下交联的含硅基团；和一种胍化合物 (B-1)，作为硅醇缩合催化剂 (B)，由通式 (1) 表示： R1N=C(NR12)2 (1) (其中五个 R1s 中的一个为芳基，另外四个 R1s 分别独立地为氢原子或碳原子位于第 1 位为饱和的烃基）。
• Hessing,A.; Peppmoeller,R., Zeitschrift fur Naturforschung. Teil B: Chemie, Biochemie, Biophysik, Biologie, 1967, vol. 22, p. 820 - 824
  作者：Hessing,A.、Peppmoeller,R.

  DOI：——

  日期：——